Malaria Vaccine: Pfs25-Pvs25

疟疾疫苗：Pfs25-Pvs25

• 批准号: 8336229
• 负责人: Patrick Duffy
• 金额: $ 35.4万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8336229
• 关键词: Adjuvant; Aluminum; Animals; Area; Collaborations; Conjugate Vaccines; Culicidae; Development; Human; Immune Sera; Investigation; Investigational New Drug Application; Laboratories; Malaria; Malaria Vaccines; Molecular Immunology; National Institute of Child Health and Human Development; Parasites; Phase I Clinical Trials; Plasmodium falciparum; Proteins; Published Comment; Recombinants; Safety; Staging; Surface; Vaccines; burden of illness; developmental immunology; immunogenicity; response; safety testing; transmission process

In collaboration with Drs. John Robbins and Rachel Schneerson at the Laboratory of Developmental and Molecular Immunology of the NICHD, we have developed a candidate conjugate vaccine that consists of Pfs25-Pfs25 conjugates. The immune sera induced by the conjugate vaccine displayed ability to block parasite development in mosquitoes. An Investigational New Drug Application was filed with FDA, intending a Phase 1 trial to test the safety, immunogenicity, and ex-vivo transmission blocking activity in humans. In response to FDAs comment, additional animal studies were conducted to evaluate the safety in animals.

与Drs合作。 NICHD发育和分子免疫学实验室的John Robbins和Rachel Schneerson开发了一种由PFS25-PFS25共轭物组成的候选结合疫苗。结合疫苗诱导的免疫血清表现出可以阻止蚊子中寄生虫发育的能力。向FDA提出了研究性新药物应用，该应用打算进行1期试验，以测试人类的安全性，免疫原性和前体传播阻断活性。 为了回应FDA评论，进行了其他动物研究以评估动物的安全性。